PHARMA LITERATI

Drug Name Luseogliflozin Structure   Drug Code TS-071 Synonym (2S,3R,4R,5S,6R)-2-[5-(4-Ethoxybenzyl)-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol Molecular Formula C 23 H 30 O 6 S Innovator Taisho Toyama Pharmaceutical Novartis for marketing Condition Type-2 diabetes mellitus Mechanism of Action Sodium-glucose transporter 2 inhibitor Clinical Phase I Approval Approved in Japan in March 2014.

Drug Name Ranirestat Structure   Drug Code AS-3201 Synonym (3R)-2'-(4-bromo-2-fluorobenzyl)-1'H,2H,5H-spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5(2'H)-tetrone Molecular Formula C 17 H 11 BrFN 3 O 4 Innovator Dainippon Sumitomo Pharma PharmaKyorin Condition Diabetic nephropathy (Orphan drug status) Mechanism of Action Aldose reductase inhibitor Clinical Phase III in USA

A CV is a glimpse into the life of a professional. For any given job vacancy, it is safe to say that there are way more number of job applicants than the number of vacant positions. Hence, what the employer does is just scan through your CV. So technically speaking, you have a just a minute (in the best case scenario) to impress the employer to at least call you for an interview.   We at Pharma Literati know how hard it is to make an impeccable CV. Especially for the fresher job seekers. As students, we are exposed to a side of pharmacy which is not enough for the industry. They want more. We at Pharma Literati are here to bridge the gap through our  ‘Career Development Initiative’.   As a part of this new ‘Career Development Initiative’, we are starting a 'CV analysis initiative'. Please send us your details or your CV and we’ll tweak it in a way that it will be impressive! Don’t hesitate to send us a mail on  pharmaliterati@gmail.com  along with the necessary detai

Drug Name (S)-Pyrrolidine-2-carboxylic acid compound with (2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1) Structure   Drug Code LIK-066 Synonym - Molecular Formula C 23 H 28 O 7 .2 C 6 H 11 NO Innovator Novartis Condition Type-2 diabetes mellitus Mechanism of Action Sodium-glucose transporter 2 inhibitor Clinical Phase II in USA

Drug Name Ertugliflozin Structure Drug Code MK-8835 Synonym PF-04971729 Molecular Formula C 22 H 25 ClO 7 Innovator Merck & Pfizer Condition Type 2 Diabetes Mellitus Mechanism of Action Sodium-glucose transporter 2 inhibitor Clinical Phase III in USA

Apple is pushing deeper into the business of health. At its  event this morning , the company unveiled its newest software in the field: CareKit, an open source tool for building apps that lets iPhone owners track their medical data and share it with doctors. Apple is starting with an app designed for Parkinson’s disease patients. And while Google’s efforts there — primarily with Verily, the medical research arm under Alphabet — are far  more advanced scientifically, Apple has a considerable advantage in the race to seize the health-tracking market. It can turn every iPhone into a health-tracking device. That seems to be Apple’s goal with its latest software product. It starts with convincing iPhone owners to share their bodily habits with their device (how many steps did I take today?) but would progress to turning the iPhone into an electronic medical research database — a potentially lucrative asset in the medical industry.

This series will take you through the future of drugs. Which drugs are in the pipeline of which company, which clinical phase are they in during trials? We have all the answers.                We are going to start with diabetes since it is one of the biggest monsters plaguing India since decades.  According to statistics and surveys, India has the most number of diabetics in the world. Hence, in this series, we are going to take you through the most promising few candidates against diabetes in the future. These drugs might shape the Pharma market for diabetes and we can be rest assured that we might have newer drugs for this deadly disease. Drug Name Bexagliflozin Structure Drug Code EGT 0001442 Synonym THR-1442 Molecular Formula C 24 H 29 ClO 7 Innovator Theracos (US based company) Condition Type 2 Diabetes Mellitus Mechanism of Action Sodium-glucos

1.    Aceclofenac + Paracetamol + Rabeprazole 2.    Nimesulide + Diclofenac 3.    Nimesulide + Cetirizine + Caffeine 4.    Nimesulide + Tizanidine 5.    Paracetamol + Cetirizine + Caffeine 6.    Diclofenac + Tramadol + Chlorzoxazone 7.    Dicyclomine + Paracetamol + Domperidone 8.    Nimesulide + Paracetamol dispersible tablets 9.    Paracetamol + Phenylephrine + Caffeine 10. Diclofenac + Tramadol + Paracetamol 11. Diclofenac + Paracetamol + Chlorzoxazone + Famotidine 12. Naproxen + Paracetamol 13. Nimesulide + Serratiopeptidase 14. Paracetamol + Diclofenac + Famotidine 15. Nimesulide + Pitofenone + Fenpiverinium + Benzyl Alcohol 16. Omeprazole + Paracetamol + Diclofenac 17. Nimesulide + Paracetamol injection 18. Tamsulosin + Diclofenac 19. Paracetamol + Phenylephrine + Chlorpheniramine + Dextromethorphan + Caffeine 20. Diclofenac + Zinc Carnosine 21. Diclofenac + Paracetamol + Chlorpheniramine Maleate + Magnesium Trisillicate 22